Advertisement

Topics

Edison Investment Research Limited: Edison Issues ADR Outlook on Hutchison China MediTech (HCM)

09:56 EDT 5 Jul 2019 | FinanzNachrichten

LONDON, UK / ACCESSWIRE / July 5, 2019 / Hutchison China MediTech (HCM) has announced positive data that key late-stage asset surufatinib met the primary endpoint of PFS in non-pancreatic at the Ph...

Original Article: Edison Investment Research Limited: Edison Issues ADR Outlook on Hutchison China MediTech (HCM)

NEXT ARTICLE

More From BioPortfolio on "Edison Investment Research Limited: Edison Issues ADR Outlook on Hutchison China MediTech (HCM)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...